Mineralys Therapeutics Achieves Proteomic Signal for Lorundrostat Ahead of December 2026 PDUFA Date

With a PDUFA target date of December 22, 2026, Mineralys Therapeutics has added a proteomic dimension to lorundrostat's regulatory dossier, one that QA and regulatory leads will want to read against the FDA's evolving expectations for pharmacodynamic characterisation in novel mechanism submissions. The company presented a post hoc proteomic analysis at ENDO 2026 in Chicago showing lorundrostat's association with significant reductions in heart failure risk biomarkers across 1,004 participants from its Phase 3 Launch-HTN and Phase 2b Advance-HTN trials.

The analysis profiled circulating protein biomarkers at baseline and at 12 weeks. Lorundrostat was associated with significant reductions in 6 of 11 candidate causal risk biomarkers of incident heart failure, including NT-proBNP. Confirmed target engagement was demonstrated through significant increases in renin and decreases in angiotensinogen, consistent with aldosterone synthase inhibition acting on the renin-angiotensin-aldosterone system.

For regulatory affairs leads, the mechanistic coherence of the dataset carries weight. The analysis showed coordinated changes across biomarker clusters: reductions in markers of fibrosis and heart failure risk alongside increases in markers of hemostasis and protease inhibitor activity. The coordinated directionality of these shifts strengthens the biological plausibility argument for RAAS modulation and supports the hypothesis that lorundrostat acts on fibrotic pathways implicated in heart failure pathophysiology, rather than producing isolated, non-specific proteomic noise.

From a CMC and manufacturing readiness standpoint, lorundrostat's status as a novel aldosterone synthase inhibitor means that process validation packages and analytical method development will need to reflect a compound entering a largely uncharted commercial pathway. The absence of a prior approved agent in this class places additional scrutiny on comparability data and release specifications as Mineralys moves toward potential commercialisation.

The data were presented as a late-breaking poster, a designation that signals the findings were submitted after the standard abstract deadline, typically reflecting emerging clinical or mechanistic relevance. Mineralys characterised the results as hypothesis-generating, supporting further evaluation of lorundrostat in heart failure settings beyond its current hypertension indication under review.

The FDA's review clock continues toward the December 22, 2026 PDUFA date, at which point the adequacy of Mineralys's full submission package, including CMC documentation for a first-in-class aldosterone synthase inhibitor, will determine whether lorundrostat reaches the commercial manufacturing stage.

Source: Mineralys Therapeutics, Inc. via GlobeNewswire, June 14, 2026.